Biotech Growth N V - Mar 19, 2025 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
10%+ Owner
Signature
/s/ Ivo Betschart
Stock symbol
BDTX
Transactions as of
Mar 19, 2025
Transactions value $
-$11,997,749
Form type
4
Date filed
3/20/2025, 09:01 PM
Previous filing
Nov 5, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Sale -$2.07M -1M -11.74% $2.07 7.52M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$583K -300K -3.99% $1.94 7.22M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$2.31M -1M -13.85% $2.31 6.22M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$4M -2M -32.17% $2.00 4.22M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$837K -400K -9.48% $2.09 3.82M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$1.14M -584K -15.3% $1.95 3.23M Mar 19, 2025 Direct
transaction BDTX Common Stock Sale -$1.06M -500K -15.46% $2.12 2.73M Mar 19, 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Biotech Growth N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Black Diamond Therapeutics, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.